{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:55:02Z","timestamp":1762419302266,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":160,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.rceng.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T20:38:42Z","timestamp":1682455122000},"page":"340-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: A real-world experience from Spain"],"prefix":"10.1016","volume":"223","author":[{"given":"E.","family":"Rodilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.I.","family":"Orts-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Sanz-Caballer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"Gimeno-Brosel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Arilla-Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Navarro-Gonzalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Castillo-Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Salvador-Mercader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Carral-Tatay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2023.04.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2261-13-31","article-title":"An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): The UK protocol","volume":"13","author":"Apenteng","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"10.1016\/j.rceng.2023.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Eng J Med"},{"issue":"11","key":"10.1016\/j.rceng.2023.04.005_bib0015","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Eng J Med"},{"issue":"10","key":"10.1016\/j.rceng.2023.04.005_bib0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Eng J Med"},{"issue":"4","key":"10.1016\/j.rceng.2023.04.005_bib0025","first-page":"754","article-title":"Dabigatran in real-world atrial fibrillation: Meta-analysis of observational comparison studies with vitamin K antagonists","volume":"116","author":"Carmo","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rceng.2023.04.005_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ahj.2017.08.018","article-title":"Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry","volume":"198","author":"Huisman","year":"2018","journal-title":"Am Heart J"},{"issue":"14","key":"10.1016\/j.rceng.2023.04.005_bib0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.rceng.2023.04.005_bib0040","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \u201creal-world\u201d clinical practice: A propensity-matched analysis of 76,940 patients","volume":"117","author":"Li","year":"2017","journal-title":"Thromb Haemost"},{"issue":"38","key":"10.1016\/j.rceng.2023.04.005_bib0045","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.rceng.2023.04.005_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.rceng.2023.04.005_bib0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.recesp.2019.02.003","article-title":"Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study","volume":"73","author":"Anguita S\u00e1nchez","year":"2020","journal-title":"Rev Esp Cardiol (English Edition)"},{"issue":"14","key":"10.1016\/j.rceng.2023.04.005_bib0060","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2217\/cer-2019-0079","article-title":"Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and Vitamin K antagonists: A Spanish real-world study","volume":"8","author":"Ramagopalan","year":"2019","journal-title":"J Comp Eff Res"},{"issue":"3","key":"10.1016\/j.rceng.2023.04.005_bib0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/cer-2018-0134","article-title":"Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: Outcomes from the first observational and prospective study in a Spanish population","volume":"8","author":"Cerd\u00e1","year":"2019","journal-title":"J Comp Eff Res"},{"issue":"11","key":"10.1016\/j.rceng.2023.04.005_bib0070","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"author":"R Core Team","key":"10.1016\/j.rceng.2023.04.005_bib0075"},{"issue":"1","key":"10.1016\/j.rceng.2023.04.005_bib0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"2015","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"5","key":"10.1016\/j.rceng.2023.04.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.semerg.2017.09.005","article-title":"Diferencias en el manejo de los pacientes con fibrilaci\u00f3n auricular seg\u00fan inicie el tratamiento con anticoagulantes orales de acci\u00f3n directa el m\u00e9dico de atenci\u00f3n primaria o el especialista. Estudios SILVER-AP y BRONCE-AP","volume":"44","author":"de la Figuera","year":"2017","journal-title":"Semergen"},{"issue":"6","key":"10.1016\/j.rceng.2023.04.005_bib0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.aprim.2017.05.009","article-title":"Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study","volume":"50","author":"de la Figuera","year":"2018","journal-title":"Aten Primaria"},{"issue":"6","key":"10.1016\/j.rceng.2023.04.005_bib0095","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1074248418778544","article-title":"Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia","volume":"23","author":"Gomez-Lumbreras","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.rceng.2023.04.005_bib0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/cer-2017-0034","article-title":"Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: The ESPARTA study","volume":"7","author":"Mostaza","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"4","key":"10.1016\/j.rceng.2023.04.005_bib0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.carcor.2018.04.002","article-title":"Patients with non-valvular atrial fibrillation treated with rivaroxaban in Spain: unequal access to oral direct anticoagulants (HEROIC study)","volume":"53","author":"Peris Vidal","year":"2018","journal-title":"Cardiocore"},{"issue":"2","key":"10.1016\/j.rceng.2023.04.005_bib0110","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/bcp.14430","article-title":"Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study","volume":"87","author":"Rodr\u00edguez-Bernal","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.rceng.2023.04.005_bib0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ehjcvp\/pvz086","article-title":"Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: A nationwide cohort study","volume":"6","author":"Rutherford","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"10.1016\/j.rceng.2023.04.005_bib0120","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/STROKEAHA.120.028825","article-title":"Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: The NAXOS study","volume":"51","author":"van Ganse","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.rceng.2023.04.005_bib0125","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3389\/fphar.2020.583311","article-title":"Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: A systematic review and meta-analysis","volume":"11","author":"Grymonprez","year":"2020","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.rceng.2023.04.005_bib0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.33588\/rn.6406.2016311","volume":"64","author":"Monreal-Bosch","year":"2017","journal-title":"Rev Neurol"},{"issue":"11","key":"10.1016\/j.rceng.2023.04.005_bib0135","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2010.05.028","article-title":"Age as a risk factor for stroke in atrial fibrillation patients: Implications for thromboprophylaxis","volume":"56","author":"Marinigh","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"7792","key":"10.1016\/j.rceng.2023.04.005_bib0140","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.rceng.2023.04.005_bib0145","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: A biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.rceng.2023.04.005_bib0150","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/STROKEAHA.118.021047","article-title":"Age threshold for ischemic stroke risk in atrial fibrillation cohort data covering the entire Korean population","volume":"49","author":"Kim","year":"2018","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.rceng.2023.04.005_bib0155","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.rceng.2023.04.005_bib0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005657","article-title":"Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: A sub-analysis from the PREFER in AF (PREvention of thromboembolic events-european registry in atrial fibrillation)","volume":"6","author":"Patti","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.rceng.2023.04.005_bib0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/clc.22373","article-title":"Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking Rivaroxaban","volume":"38","author":"Tamayo","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.rceng.2023.04.005_bib0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2020.06.032","article-title":"Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience","volume":"320","author":"Akhtar","year":"2020","journal-title":"Int J Cardiol"},{"issue":"24","key":"10.1016\/j.rceng.2023.04.005_bib0175","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.rceng.2023.04.005_bib0180","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CRD.0000000000000088","article-title":"Non-vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: A meta-analysis of randomized controlled trials","volume":"24","author":"Kumar","year":"2016","journal-title":"Cardiol Rev"},{"issue":"10","key":"10.1016\/j.rceng.2023.04.005_bib0185","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/clc.22750","article-title":"Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events","volume":"40","author":"Lemesle","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.rceng.2023.04.005_bib0190","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1060028018771264","article-title":"Gender differences in efficacy and safety of direct oral anticoagulants in atrial fibrillation: Systematic review and network meta-analysis","volume":"52","author":"Raccah","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rceng.2023.04.005_bib0195","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: Insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2023.04.005_bib0200","first-page":"3268","article-title":"Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial","volume":"36","author":"Vinereanu","year":"2015","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.rceng.2023.04.005_bib0205","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: A systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.rceng.2023.04.005_bib0210","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","article-title":"Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients &75 years of age","volume":"123","author":"Malik","year":"2019","journal-title":"Am J Cardiol"},{"issue":"FI1","key":"10.1016\/j.rceng.2023.04.005_bib0215","doi-asserted-by":"crossref","first-page":"f11","DOI":"10.1093\/ehjcvp\/pvab002","article-title":"Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of 605 771 patients","volume":"7","author":"Menichelli","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"10.1016\/j.rceng.2023.04.005_bib0220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11239-017-1565-2","article-title":"High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy","volume":"44","author":"Manzoor","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rceng.2023.04.005_bib0225","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-020-02367-2","article-title":"Switching between direct oral anticoagulants: A systematic review and meta-analysis","author":"Romoli","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.rceng.2023.04.005_bib0230","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2459\/JCM.0000000000001118","article-title":"Switching across direct oral anticoagulants: A real-life-setting pilot prospective study","volume":"22","author":"Marchetti","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"6","key":"10.1016\/j.rceng.2023.04.005_bib0235","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.rceng.2023.04.005_bib0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/joim.12683","article-title":"Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"283","author":"Staerk","year":"2018","journal-title":"J Intern Med"},{"issue":"10","key":"10.1016\/j.rceng.2023.04.005_bib0245","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/europace\/eux316","article-title":"Inappropriate doses of direct oral anticoagulants in real-world clinical practice: Prevalence and associated factors. A subanalysis of the FANTASIIA registry","volume":"20","author":"Ruiz Ortiz","year":"2018","journal-title":"Europace"},{"issue":"7323","key":"10.1016\/j.rceng.2023.04.005_bib0250","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study","volume":"323","author":"Devereaux","year":"2001","journal-title":"Br Med J"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887423000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887423000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:50:11Z","timestamp":1762419011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887423000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2254887423000553"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2023.04.005","relation":{},"ISSN":["2254-8874"],"issn-type":[{"type":"print","value":"2254-8874"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: A real-world experience from Spain","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2023.03.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}